Clinical Trial Update: Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated insulin sensitivity and intramyocellular lipid content in glucose-intolerant subjects receiving rosiglitazone; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucose Intolerance
• Insulin Resistance

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Insulin Sensitivity | Phase 4 | Status: COMPLETED